...
首页> 外文期刊>American Journal of Case Reports >Successful Hepatitis C Antiviral Therapy Induces Remission of Type 2 Diabetes: A Case Report
【24h】

Successful Hepatitis C Antiviral Therapy Induces Remission of Type 2 Diabetes: A Case Report

机译:成功的丙型肝炎抗病毒治疗诱导2型糖尿病的缓解:一例报告

获取原文
           

摘要

Patient: Male, 49 Final Diagnosis: Type 2 diabetes Symptoms: — Medication: — Clinical Procedure: — Specialty: Endocrinology and Metabolic Objective: Unusual clinical course Background: Type 2 diabetes is a well described extra-hepatic manifestation of hepatitis C infection (HCV). Eradication of HCV has led to improvements in insulin resistance but to date has not been shown to induce remission of diabetes. Case Report: We report a case of a 49-year-old man with HCV and a 2-year history of T2DM on oral agents. He was initially treated with peg-interferon/ribavirin (peg-IFN/rib) but did not achieve a HCV treatment response. Four years later he was retreated with peg-IFN/rib plus an HCV protease inhibitor (boceprevir). His HbA1c at the start of treatment was 7.9%. Antiviral response to HCV-therapy correlated with a significant improvement in glucose control without a change in diabetes therapy or improvement in adherence. He achieved a sustained virological response and within a year of completing antiviral therapy he no longer required medical therapy for diabetes. Two years after the completion of HCV treatment, the patient has maintained an HbA1c of 5.8% without any diabetes medications. Conclusions: This case provides evidence of the important relationship between HCV and diabetes and highlights the potential reversibility of glucose abnormalities with successful eradication of HCV. Increased awareness of this association may improve detection of undiagnosed HCV infection, identify patients with reversible causes of diabetes, guide therapeutic decisions for HCV treatment, and improve outcomes in patients with both diseases.
机译:患者:男,49岁最终诊断:2型糖尿病症状:—药物治疗:—临床程序:—专长:内分泌和代谢物目的:异常的临床过程背景:2型糖尿病是丙型肝炎感染(HCV)的肝外表现)。消除HCV导致胰岛素抵抗的改善,但迄今为止尚未显示出可诱导糖尿病的缓解。病例报告:我们报告了一名49岁的男性丙型肝炎患者和2年的口服T2DM病史。他最初接受了聚乙二醇干扰素/利巴韦林(peg-IFN / rib)治疗,但未达到HCV治疗反应。四年后,他接受了peg-IFN / rib加HCV蛋白酶抑制剂(boceprevir)治疗。治疗开始时他的HbA1c为7.9%。对HCV治疗的抗病毒反应与血糖控制的显着改善相关,而无需改变糖尿病治疗或依从性。他获得了持续的病毒学应答,并且在完成抗病毒治疗后的一年内,他不再需要糖尿病的药物治疗。 HCV治疗结束后的两年,患者未使用任何糖尿病药物,其HbA1c维持在5.8%。结论:该病例提供了HCV与糖尿病之间重要关系的证据,并突出了成功消除HCV后葡萄糖异常的潜在可逆性。对这种关联的认识的提高可能会改善对未诊断的HCV感染的检测,确定患有糖尿病可逆原因的患者,指导HCV治疗的治疗决策,并改善两种疾病患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号